Your browser is no longer supported. Please, upgrade your browser.
Settings
SHPG Shire plc daily Stock Chart
SHPG [NASD]
Shire plc
Index- P/E68.54 EPS (ttm)2.27 Insider Own0.10% Shs Outstand299.45M Perf Week-3.72%
Market Cap46.61B Forward P/E9.56 EPS next Y16.28 Insider Trans0.00% Shs Float299.45M Perf Month5.21%
Income703.70M PEG5.62 EPS next Q3.64 Inst Own20.30% Short Float0.51% Perf Quarter-5.69%
Sales14.58B P/S3.20 EPS this Y-65.50% Inst Trans-8.13% Short Ratio1.11 Perf Half Y-11.65%
Book/sh103.48 P/B1.50 EPS next Y9.04% ROA1.00% Target Price226.08 Perf Year-22.40%
Cash/sh- P/C- EPS next 5Y12.20% ROE2.30% 52W Range139.36 - 209.22 Perf YTD-8.64%
Dividend0.92 P/FCF- EPS past 5Y-12.80% ROI2.10% 52W High-25.87% Beta1.64
Dividend %0.59% Quick Ratio0.50 Sales past 5Y22.30% Gross Margin64.10% 52W Low11.29% ATR2.93
Employees23906 Current Ratio1.00 Sales Q/Q54.20% Oper. Margin8.40% RSI (14)50.16 Volatility1.56% 1.53%
OptionableYes Debt/Eq0.69 EPS Q/Q108.60% Profit Margin4.70% Rel Volume0.52 Prev Close155.66
ShortableYes LT Debt/Eq0.59 EarningsAug 03 BMO Payout13.20% Avg Volume1.38M Price155.10
Recom1.80 SMA202.22% SMA50-0.90% SMA200-8.45% Volume584,819 Change-0.36%
Aug-17-17Initiated Evercore ISI Outperform $196
Jun-16-17Initiated Cantor Fitzgerald Overweight $222
Jun-09-17Reiterated Jefferies Buy $239 → $216
Jun-01-17Downgrade Liberum Buy → Hold
May-26-17Downgrade Bernstein Outperform → Mkt Perform
May-19-17Downgrade HSBC Securities Hold → Reduce
Mar-09-17Initiated Liberum Buy
Dec-02-16Initiated Societe Generale Buy
Sep-26-16Downgrade HSBC Securities Buy → Hold
Jun-03-16Reiterated Jefferies Buy $223 → $262
May-26-16Initiated Stifel Buy $230
May-06-16Initiated Liberum Buy
Feb-26-16Initiated Cantor Fitzgerald Buy
Feb-10-16Upgrade RBC Capital Mkts Sector Perform → Outperform $240 → $240
Feb-10-16Initiated Guggenheim Neutral
Jan-15-16Upgrade BofA/Merrill Neutral → Buy
Jan-12-16Upgrade Credit Suisse Neutral → Outperform
Jan-12-16Reiterated RBC Capital Mkts Sector Perform $248 → $240
Nov-17-15Upgrade Leerink Partners Mkt Perform → Outperform $239
Nov-03-15Upgrade HSBC Securities Hold → Buy
Sep-18-17 10:00AM  Neos Therapeutics ADHD Drug Adzenys Receives Approval in US Zacks
Sep-15-17 07:39AM  Whats Coopermans View on Shire? Market Realist
Sep-12-17 04:38PM  Top Research Reports for Disney, Kraft Heinz & CVS Health Zacks
Sep-08-17 09:53AM  Alnylam Shares Plunge on Patient Death, Dosing Suspended Zacks
Sep-07-17 01:03PM  Here's Why Shire PLC Stock Fell 10% in August Motley Fool
Sep-01-17 06:32AM  Shire plc : Total voting rights GlobeNewswire
Aug-30-17 07:20AM  Corporate News Blog - Sanofi Completes Acquisition of Vaccines Biotechnology Company, Protein Sciences ACCESSWIRE
Aug-24-17 10:08AM  Roche (RHHBY) Hemophilia A Drug Granted Priority Review Zacks
Aug-23-17 07:02AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
05:33AM  Shire chief financial officer joins Boston ag-tech startup American City Business Journals
Aug-22-17 11:32AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Aug-21-17 01:29PM  UPDATE: Shire: There Goes the CFO! Barrons.com
09:01AM  Shire plc Director and Senior Management Changes GlobeNewswire
Aug-16-17 05:18PM  Shire Files Marketing Application for Lifitegrast in Europe Zacks
Aug-15-17 06:00AM  Shire applies for European approval of potential blockbuster eye drop American City Business Journals
04:55AM  Shire Gains as it Seeks European Approval For Dry Eye Treatment TheStreet.com
02:02AM  Shire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe GlobeNewswire
Aug-09-17 09:17AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Aug-04-17 09:47AM  Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View Zacks
02:52AM  Shire plc : Half-yearly report GlobeNewswire
Aug-03-17 02:29PM  Shire's ADHD Spinoff Idea Is Shaky Bloomberg
02:10PM  [$$] Lombard: Impatient Shire boss waits for market to catch up Financial Times
02:10PM  Shire Acq Inv Ireland Designated Activity Co -- Moody's: Shire's evaluation of neuroscience franchise credit negative Moody's
09:58AM  [$$] Shire Mulls Spinning-off or Selling Neuroscience Unit The Wall Street Journal
09:42AM  Shire tops Street 2Q forecasts Associated Press
07:53AM  Shire Surges on Baxalta Synergies and Strong Earnings Momentum TheStreet.com
07:10AM  Investor Network: Shire PLC to Host Earnings Call ACCESSWIRE
07:02AM  Shire plc : Shire reports strong Q2 2017 operating results and cash flow GlobeNewswire
Aug-01-17 07:02AM  Shire plc : Total voting rights GlobeNewswire
Jul-26-17 04:29PM  Shire Stock Rising on Takeover Talks TheStreet.com
07:01AM  Gap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students GlobeNewswire
Jul-20-17 11:08AM  New Strong Sell Stocks for July 20th Zacks
Jul-18-17 07:02AM  Shire plc : Notice of Results GlobeNewswire
07:02AM  Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody GlobeNewswire
Jul-16-17 08:18AM  [$$] Shire boss says share price at odds with drugs pipeline Financial Times
Jul-13-17 09:30AM  The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire Zacks
08:13AM  5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings Zacks
Jul-12-17 06:01PM  A Cancer Breakthrough Near FDA Approval Has a Costly Side Effect Bloomberg
09:15AM  Analyst: Shire Shares Should Rebound, But Sustained Rally Unlikely Benzinga
Jul-11-17 08:39PM  Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run TheStreet.com
04:19PM  Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data Zacks
Jul-10-17 09:47AM  Shire, Roche slug it out in billion-dollar haemophilia drug battle Reuters
Jul-07-17 09:42AM  Shire Completes NDA Filing for Hemophilia Drug with FDA Zacks
Jul-06-17 07:01AM  Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A GlobeNewswire
02:02AM  Shire plc : Additional Listing GlobeNewswire
Jul-05-17 08:03AM  3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher Motley Fool
Jul-03-17 08:32AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
07:01AM  Shire plc : Total voting rights GlobeNewswire
Jun-26-17 09:30AM  The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk Zacks
Jun-23-17 08:02AM  SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA GlobeNewswire
07:42AM  Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod Zacks
Jun-22-17 10:54AM  Shire (SHPG) Receives MAA Validation for Veyvondi by EMA Zacks
09:36AM  Biotech Movers: Shire, Bellicum, Organovo TheStreet.com
01:00AM  Shire Announces EMA Validation of Veyvondi Marketing Authorization Application for Treatment of Von Willebrand Disease PR Newswire
Jun-21-17 10:52AM  Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US Zacks
10:25AM  Shire wins FDA approval for new ADHD drug American City Business Journals
Jun-20-17 07:19PM  Shire's long-acting ADHD drug wins U.S. approval Reuters
06:48PM  Shire plc: U.S. FDA Approves Mydayis (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older PR Newswire
Jun-19-17 09:45AM  Could Shire PLC (SHPG) Be a Great Stock for Value Investors? Zacks
09:02AM  Do You Really Want to Love Your Medicines? Fortune
Jun-16-17 10:54AM  Valeant: Stop Looking in the Rearview Mirror! Barrons.com
Jun-14-17 06:00AM  10 High-Quality Foreign-Stock Bargains Morningstar
Jun-08-17 10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Shire plc (SHPG) PR Newswire
Jun-07-17 03:53PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shire plc - SHPG PR Newswire
Jun-06-17 12:03PM  Down 24.6%, is BioCryst Pharmaceuticals Stock Now a Buy? Motley Fool
Jun-05-17 07:47AM  Key FDA Events to Watch Out for in Jun 2017 Zacks
May-30-17 12:13PM  Paulson & Co. Hedge Fund Cuts Back on Health Care in Q1 Investopedia
May-25-17 03:06PM  Why BioCryst Pharmaceuticals Stock Caught Fire Today Motley Fool
07:00AM  Shire to Participate at the Jefferies Healthcare Conference PR Newswire
May-24-17 09:17AM  Ultragenyx Receives Priority Review for rhGUS from FDA Zacks
May-22-17 01:05PM  Shire and tiny Lexington biotech say hemophilia drug trial misses mark American City Business Journals
May-19-17 05:21PM  Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug Zacks
12:48PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
10:17AM  Company News for May 19, 2017 Zacks
08:15AM  Blog Coverage: Shire's Stock Price Jumped on Positive Results in Hereditary Angioedema Treatment Accesswire
07:43AM  Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More Zacks
01:00AM  Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology PR Newswire
May-18-17 05:27PM  Drugmaker Leads Industry Gains Thursday On Rare Disease Trial Investor's Business Daily
05:11PM  [$$] Biotech Investor Clarus Ventures Raising $880 Million Fund The Wall Street Journal
11:54AM  Shire's swelling disorder drug moves closer to U.S. approval Reuters
11:15AM  Shire gains $2B in market cap as rare disease drug aces late-stage trial American City Business Journals
09:00AM  The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis PR Newswire
07:18AM  Shire ADRs jump almost 7% premarket after positive trial of Angioedema treatment MarketWatch
07:00AM  Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial PR Newswire
May-16-17 04:55PM  [$$] Health-Care Investor Agent Capital Seeks $100 Million Fund The Wall Street Journal
07:00AM  Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association PR Newswire
May-15-17 04:37PM  ETFs with exposure to Shire Plc : May 15, 2017 Capital Cube
May-05-17 04:33PM  ETFs with exposure to Shire Plc : May 5, 2017 Capital Cube
10:37AM  Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat Zacks
May-04-17 11:10AM  Shire Plc :SHPG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 Capital Cube
May-03-17 11:17AM  Shire (SHPG) Beats on Q1 Earnings & Sales, Reiterates View Zacks
10:32AM  Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat Zacks
May-02-17 09:23AM  [$$] Shire Profit Pressured by Baxalta Takeover Costs The Wall Street Journal
09:10AM  Durham CEO on deal with Shire valued at up to $535M American City Business Journals
08:42AM  Shire Stock Lifted By First-Quarter Earnings Beat TheStreet.com
07:27AM  Shire tops Street 1Q forecasts Associated Press
07:00AM  Shire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage Pipeline PR Newswire
May-01-17 07:00AM  Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications PR Newswire
Apr-26-17 01:00AM  Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism PR Newswire
Apr-25-17 03:48PM  ETFs with exposure to Shire Plc : April 25, 2017 Capital Cube
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.